Unicentric Castleman disease masquerading as a gluteal mass: A diagnostic challenge.

Autor: Ahuja S; Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India., Khan AA; Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India., Khalid S; Department of Radiodiagnosis, Jawaharlal Nehru Medical College & Hospital, Aligarh Muslim University, Aligarh, India., Zaheer S; Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. Electronic address: sufianzaheer@gmail.com.

Publikováno v: Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia [Rev Esp Patol] 2024 Oct-Dec; Vol. 57 (4), pp. 300-304. Date of Electronic Publication: 2024 Jul 23.

Sirolimus is effective for refractory/relapsed idiopathic multicentric Castleman disease: A single-center, retrospective study.

Autor: Liu YT; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Gao YH; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Zhao H; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Zhang MY; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Duan MH; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Li J; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Zhang L; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. pumczhanglu@126.com.

Publikováno v: Annals of hematology [Ann Hematol] 2024 Oct; Vol. 103 (10), pp. 4223-4230. Date of Electronic Publication: 2024 May 01.

Asymptomatic multicentric Castleman disease: a potential early stage of idiopathic MCD.

Autor: Zhang L; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Liu QH; Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China., Zhou H; Department of Lymphoma & Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China., Zhang HL; Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China., Dong YJ; Department of Hematology, Peking University First Hospital, Beijing, China., Wang XB; Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, China., Wang LQ; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China., Su LP; Department of Hematology, Shanxi Province Cancer Hospital, Taiyuan, China., Yan XJ; Department of Hematology, First Hospital of China Medical University, Shenyang, China., Li Y; Department of Hematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China., Zhang MZ; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Ding KY; Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China., Wang HH; Department of Hematology, Sheng Jing Hospital of China Medical University, Shenyang, China., Peng HL; Department of Hematology, Second Xiang-ya Hospital, Central South University, Changsha, China., Zhong LY; Department of Hematology, Guangdong Provincial People's Hospital/Guangdong Academy of Medical Sciences, Guangzhou, China., Yang L; Department of Hematology, Second Hospital of Hebei Medical University, Shijiazhuang, China., Bi LT; Department of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, China., Gao D; Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China., Gao GX; Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, China., Huang L; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Sun CY; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Song J; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China., Qian WB; Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China., Huang WR; Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China., Li ZL; Department of Hematology, China-Japan Friendship Hospital, Beijing, China., Liu Y; Department of Hematology/Oncology, Chongqing University Cancer Hospital, Chongqing Cancer Hospital, Chongqing, China., Li J; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Publikováno v: Blood advances [Blood Adv] 2024 Nov 12; Vol. 8 (21), pp. 5598-5602.

Inflammasome activation in patients with Kaposi sarcoma herpesvirus-associated diseases.

Autor: Lage SL; HIV Pathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD., Ramaswami R; HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Rocco JM; HIV Pathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD., Rupert A; AIDS Monitoring Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, MD., Davis DA; HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Lurain K; HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Manion M; HIV Pathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD., Whitby D; Viral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, MD., Yarchoan R; HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Sereti I; HIV Pathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Publikováno v: Blood [Blood] 2024 Oct 03; Vol. 144 (14), pp. 1496-1507.

Pediatric TAFRO syndrome: A multi-institution case series illustrating clinical challenges and excellent outcomes.

Autor: Johnson AK; Division of Pediatric Hematology/Oncology, University of Utah/Intermountain Health Primary Children's Hospital, Salt Lake City, Utah, USA., Goteti S; Division of Pediatric Hematology/Oncology, University of Utah/Intermountain Health Primary Children's Hospital, Salt Lake City, Utah, USA., Devald B; Division of Pediatric Hematology/Oncology, University of Utah/Intermountain Health Primary Children's Hospital, Salt Lake City, Utah, USA., Mestnik S; Division of Pediatric Hematology/Oncology, University of Minnesota/M Health Fairview Masonic Children's Hospital, Minneapolis, Minnesota, USA., Ghosh T; Division of Pediatric Hematology/Oncology, University of Utah/Intermountain Health Primary Children's Hospital, Salt Lake City, Utah, USA., Williams R; Division of Pediatric Hematology/Oncology, University of Minnesota/M Health Fairview Masonic Children's Hospital, Minneapolis, Minnesota, USA., Doughty ES; Department of Pathology, University of Utah, Salt Lake City, Utah, USA., Linden MA; Department of Pathology, University of Minnesota/M Health Fairview Masonic Children's Hospital, Minnesota, Minneapolis, USA., Beckman A; Department of Pathology, University of Minnesota/M Health Fairview Masonic Children's Hospital, Minnesota, Minneapolis, USA., Williams T; Department of Pathology, Oregon Health & Science University/Doernbecher Children's Hospital, Oregon, Portland, USA., Richardson K; Division of Pediatric Nephrology, Oregon Health & Science University/Doernbecher Children's Hospital, Portland, Oregon, USA., Martinelli M; Division of Pediatric Hematology/Oncology, Oregon Health & Science University/Doernbecher Children's Hospital, Portland, Oregon, USA.

Publikováno v: Pediatric blood & cancer [Pediatr Blood Cancer] 2024 Oct; Vol. 71 (10), pp. e31234. Date of Electronic Publication: 2024 Jul 31.